Prothena Corp. (PRTA) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Broadcom, Apple extend chip supply deal through 2031
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
- Strategy reports $8.32B bitcoin loss and sells BTC to fund dividends
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024 4:05 PM ESTNet cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinsons disease from the Phase 2... More
